Nordic Drugs

What Nordic Drugs does

Nordic Drugs AB is a Nordic pharmaceutical company headquartered in Malmö, Sweden, founded in 1995 and operating as the Scandinavian regional subsidiary of the pan-European Nordic Pharma Group (parent since 2001). The company sells both proprietary and licensed specialty pharmaceutical products across more than ten therapeutic areas including rheumatology, pain/inflammation, addiction care, oncology, hematology, women's health, gastroenterology, ophthalmology, hemostatics, cardiovascular, and infectious disease, with key brands such as Gaviscon (OTC reflux), Nordimet (methotrexate injection pen for rheumatoid arthritis), Metadon Nordic Drugs (25-strength methadone for opioid dependence), Teysuno (oral 5-FU combination for advanced gastric and metastatic colorectal cancer), Mifegyne and Topogyne (medical abortion regimen), Hyalobarrier (anti-adhesion gel), Trasylol (aprotinin for cardiac surgery), and Lacrifill (ophthalmic canalicular gel).

The company's technology base comprises proprietary drug formulations, drug delivery devices, and CE-marked medical devices, supported by in-house production in Malmö (for Nordimet and Gaviscon) and dedicated regulatory, pharmacovigilance, and quality assurance functions. Nordimet's self-injection pen addresses methotrexate administration ease; Metadon Nordic Drugs offers color-coded, alcohol-free oral formulations designed to deter misuse; Teysuno combines tegafur with DPD and OPRTase inhibitors to improve 5-FU tolerability; Lacrifill's crosslinked hyaluronate enables canalicular occlusion for dry-eye management.

Nordic Drugs operates a sales-led go-to-market model with field sales organizations in Sweden, Denmark, Finland, Norway, and Iceland, distributing through pharmacy channels (both prescription Rx and OTC). Revenue is generated via unit pricing on dispensed pharmaceutical products, with pricing publicly available only through the Swedish FASS database. The customer base consists of healthcare professionals across multiple specialties and end consumers purchasing OTC products. The company maintains EFPIA transparency disclosures, EcoVadis Silver sustainability rating (top 15%, 2025), PSCI membership, and GRI-aligned CSR reporting. Recent strategic activity centers on the 2025 Lacrifill CE marking, ophthalmology franchise buildout (KAM recruitment, congress presence at ESCRS/EuCORNEA), and the June 2025 launch of the NordiMEET-Rheumatology educational platform.

Name

Nordic Drugs

Legal name

Nordic Drugs AB

Website

https://www.nordicdrugs.se/

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Nordic Drugs is a pharmaceutical company that offers medicine for gastrointestinal, women's health, oncology, and hemostatic treatments.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

OTC & Consumer Health Distributors (HLAIAJAC)

akta.pro secondary industries

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Specialty pharmaceuticals
• Prescription drugs
• Over-the-counter medications
• Rheumatology therapeutics
• Women's health pharmaceuticals

Headquarters

HQ city

Limhamn

HQ country

Sweden

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: Nordic Drugs generates revenue through the sale of proprietary and licensed pharmaceutical products across specialty therapeutic areas including rheumatology, pain, addiction care, oncology, hematology, women's health, gastroenterology, ophthalmology, hemostatics, and cardiovascular products. The company sells both prescription (Rx) and over-the-counter (OTC) products.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels8 records

Core offering

Nordic Drugs develops, manufactures, licenses, and distributes specialty pharmaceutical products across multiple therapeutic areas including rheumatology, pain/inflammation, addiction treatment, oncology, hematology, women's health, gastroenterology, ophthalmology, hemostatics, cardiovascular, and infection. The company markets both prescription (Rx) and over-the-counter (OTC) products to healthcare professionals and patients in the Nordic region through its own sales organizations in Sweden, Denmark, Finland, Norway, and Iceland, with production based in Malmö, Sweden.

Product overview

Nordic Drugs is a Nordic pharmaceutical company founded in 1995, headquartered in Malmö with sales organizations in Denmark, Finland, Norway, and Iceland. The company offers a portfolio of both proprietary and licensed pharmaceutical products spanning multiple therapeutic areas: rheumatology (Nordimet methotrexate injection pen), pain/inflammation (Tradil dexibuprofen, Allopurinol), addiction treatment (Metadon Nordic Drugs oral solution), oncology (Teysuno oral cancer drug), hematology (Trasylol aprotinin for blood loss reduction), women's health (Mifegyne mifepristone, Topogyne misoprostol, Hyalobarrier hyaluronic acid gel), gastroenterology (Gaviscon reflux remedy, Dimor loperamide, Hidrasec racecadotril, Cilaxoral sodium picosulfate, PROIBS MD), cold/cough (Nasoferm xylometazoline), cardiovascular (Amiloferm), infection (Doxyferm doxycycline, Flagyl metronidazole), and ophthalmology (Lacrifill canalicular gel for dry eye, newly CE-marked in 2025). The company also operates the NordiMEET educational platform for healthcare professionals. Nordic Drugs operates under the paneuropean Nordic Pharma Group.

Differentiator

Problem solved

Functional benefit

Brands

• Nordimet: Methotrexate injection pen for rheumatoid arthritis treatment
• Gaviscon
• Metadon Nordic Drugs
• Nasoferm
• Lacrifill
• Teysuno
• Mifegyne
• Topogyne
• Hyalobarrier
• Trasylol
• Nordic Drugs Stora Pris

Products and services

• Nordimet (methotrexate) injection pen

Quantifiable outcome

• Mifegyne (mifepristone) combined with prostaglandin achieves approximately 95% complete abortion rate in first trimester
• +5 more outcomes

Named customers2 records

Segments8 records

Ideal customer profiles8 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Rosenlunds Mödravårdsteam (Beroendecentrum Stockholm)minorOthers · 1 October 2025Rosenlunds Mödravårdsteam at Beroendecentrum Stockholm received the Nordic Drugs Stora Pris 2025 scholarship (50,000 SEK) for their work developing addiction treatment for pregnant women and their partners with harmful alcohol or drug use. The team offers specialized care including parenting education, relapse prevention, psychological support, and pediatrician/child psychiatrist consultations.
• Orbis UKcoreStrategic or Co-development Partner · 1 January 2025Nordic Pharma partnership with Orbis UK to support global eye care access and eliminate avoidable blindness. Activities include Digital Cleanup Day (where digital cleanup steps translate to donations to Orbis), World Sight Day 2025 support, and the 30-year anniversary step challenge donation to Orbis International targeting eye care programs in Southwest Ethiopia.
• Svensk Förening för BeroendemedicincoreStrategic or Co-development Partner · 1 January 2025Nordic Drugs collaborates annually with Svensk Förening för Beroendemedicin (Swedish Society of Addiction Medicine) to award the Nordic Drugs Stora Pris scholarship, recognizing healthcare teams making significant contributions to addiction medicine development. The partnership has awarded this prestigious scholarship for 15 consecutive years.
• BowerminorGTM or Marketing Partner · 1 January 2024Nordic Drugs partnered with Bower, a digital recycling app with over 600,000 users and 73 million packages recycled, enabling consumers to scan and recycle Nasoferm and Gaviscon packaging and earn points redeemable for money, coupons, or charitable donations. This supports Nordic Drugs' sustainability vision and more sustainable resource use.
• Moorfields Eye Hospital (London)coreStrategic or Co-development PartnerNordic Pharma hosted the Nordic Pharma Dry Eye Excellence Course at Moorfields Education Hub, featuring expert-led sessions from Professor Sajjad Ahmad and Mr Daniel Sibley on dry eye disease management, peri-surgical care, and TFOS DEWS III updates. The partnership advances ophthalmology education and Nordic Pharma's ocular surface control expertise.
• Healthcare professionals and patient organizationscoreStrategic or Co-development PartnerNordic Drugs continuously collaborates with healthcare systems and patient/organization groups. These collaborations are essential for pharmaceutical development focused on patients' medical needs. The company follows EFPIA transparency guidelines, publishing annual value transfer reports.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Orion Corporation: Orion Corporation is a Finnish specialty pharmaceutical company operating across multiple therapeutic areas with both proprietary and licensed products, including OTC and Rx offerings. Highly comparable as a Nordic specialty pharma with similar geographic focus and multi-therapeutic portfolio approach.
• Swedish Orphan Biovitrum (SOBI): SOBI is a Swedish specialty pharmaceutical company focused on rare diseases and specialty care, headquartered in Stockholm. Comparable as a Swedish-headquartered specialty pharma with similar multi-country Nordic/European distribution approach and focus on niche therapeutic areas with high unmet need.
• LEO Pharma: LEO Pharma is a Danish specialty pharmaceutical company with global presence focused on dermatology and thrombosis. Comparable as a Nordic-headquartered specialty pharma with strong Nordic market presence, proprietary product development, and a research-driven approach to niche therapeutic areas.
• Stada Arzneimittel: Stada is a European specialty pharmaceutical company focused on generics, OTC, and specialty pharma across multiple therapeutic areas. Comparable as a pan-European specialty pharma with a similar mix of proprietary and licensed products, OTC brand focus (e.g., Grippostad), and multi-country European distribution.
• Almirall: Almirall is a Spanish specialty pharmaceutical company focused on dermatology and specialty care across Europe. Comparable as a European specialty pharma with a multi-therapeutic area portfolio, strong OTC presence in European markets, and focus on niche indications with high medical need.
• Recordati: Recordati is an Italian specialty pharmaceutical group with European focus across rare diseases, specialty, and primary care. Comparable as a European specialty pharma with proprietary and licensed products, OTC brands, and a multi-therapeutic area portfolio similar to Nordic Drugs.
• Ipsen: Ipsen is a French specialty pharmaceutical company focused on oncology, neurology, and rare diseases. Comparable as a European specialty pharma with strong presence in niche therapeutic areas (particularly oncology, similar to Nordic Drugs' Teysuno franchise) and a multi-country distribution model.
• Ferring Pharmaceuticals: Ferring is a Swiss-headquartered specialty pharmaceutical company with strong Nordic ties, focused on reproductive health, gastroenterology, and urology. Highly comparable as Nordic Drugs shares therapeutic area overlap in women's health (Mifegyne/Topogyne) and gastroenterology (Gaviscon, Dimor, Cilaxoral).

Regional players

• Recipharm: Recipharm is a Swedish pharmaceutical contract development and manufacturing organization (CDMO). Adjacent comparison as a Nordic-headquartered pharma industry player; not directly competing but provides context for Nordic pharma sector scale and ecosystem.

Broad incumbents

• Viatris: Viatris is a global pharmaceutical company formed through the Mylan-Upjohn merger that acquired Swedish specialty pharma Meda. Comparable as a broad incumbent offering generics, branded, and OTC products across many of the same therapeutic areas as Nordic Drugs, with prior Nordic specialty exposure via the Meda acquisition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInse.linkedin.com/company/nordic-drugs

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordic Drugs